Furthermore, Csnk1a1 haploinsufficiency was shown to sensitize cells to casein kinase inhibition, indicating that CSNK1A1 is a potential new therapeutic target for the treatment of del(5q) MDS.15 This evidence concerns the gene CSNK1A1 and myelodysplastic syndrome.